MOONLAKE IMMUNOTHERAPEUTICS Total Liabilities and Equity
MOONLAKE IMMUNOTHERAPEUTICS (MLTX) had Total Liabilities and Equity of $573.95 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Balance Sheet
us-gaap:LiabilitiesAndStockholdersEquity · last filed 2026-08-10
- 2026-06-30: Liabilities and Equity $573.95M.
- 2026-03-31: Liabilities and Equity $400.37M.
- 2025-12-31: Liabilities and Equity $424.43M.
- 2025-09-30: Liabilities and Equity $414.33M.
| Period end | Liabilities and Equity | Liabilities and Equity as first filed |
|---|---|---|
| 2026-06-30 | $573.95M 10-Q · filed 2026-08-10 | |
| 2026-03-31 | $400.37M 10-Q · filed 2026-05-11 | |
| 2025-12-31 | $424.43M 10-Q · filed 2026-08-10 | |
| 2025-09-30 | $414.33M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $460.10M 10-Q · filed 2025-08-05 | |
| 2025-03-31 | $511.26M 10-Q · filed 2025-05-12 | |
| 2024-12-31 | $477.93M 10-K · filed 2026-02-25 | $477.93M 10-K · filed 2025-02-26 |
| 2024-09-30 | $518.21M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $544.88M 10-Q · filed 2024-08-07 | |
| 2024-03-31 | $564.12M 10-Q · filed 2024-05-07 | |
| 2023-12-31 | $526.54M 10-K · filed 2025-02-26 | |
| 2023-09-30 | $500.22M 10-Q · filed 2023-11-14 | |
| 2023-06-30 | $506.62M 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $66.80M 10-Q · filed 2023-05-11 | |
| 2022-12-31 | $76.84M 10-K · filed 2024-02-29 | |
| 2022-09-30 | $88.59M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $98.43M 10-Q · filed 2022-08-12 | |
| 2022-03-31 | $231.21M 10-Q · filed 2022-05-16 | |
| 2021-12-31 | $9.68M 10-K · filed 2023-03-20 | $115.84M 10-K · filed 2022-02-17 |
| 2021-09-30 | $116.25M 10-Q/A · filed 2021-12-14 | |
| 2021-06-30 | $116.37M 10-Q · filed 2021-08-16 | |
| 2021-03-31 | $116.49M 10-Q · filed 2021-05-21 | |
| 2020-12-31 | $116.63M 10-K · filed 2022-02-17 | |
| 2020-09-30 | $163.51K 10-Q · filed 2020-12-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |